Sign In
Last checked at 
25 Jul 2018 14:45
25 July 2018
Scancell Holdings plc
("Scancell" or the "Company")
PDMR Dealing
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer announces the following director share sale and re-purchase transaction, undertaken to satisfy a charge in relation to a SIPP.
On 24 July 2018, Dr John Chiplin sold 2,483 ordinary shares at 11 pence per ordinary share and on 25 July 2018, Dr John Chiplin purchased 2,483 ordinary shares at 11.7 pence per ordinary share. Following the transaction, Dr John Chiplin's total interest of 2,000,000 remains unchanged, representing 0.52% of the total voting rights.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Dr John Chiplin |
2 | Reason for the notification | |
a) | Position/status | Chairman and PDMR |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Sale of Ordinary Shares |
d) | Price(s) and volume(s) | 2,483 Ordinary Shares 11 pence per Ordinary Share |
e) | Aggregated information - Aggregated volume - Price |
2,483 Ordinary Shares 11 pence per Ordinary Share |
f) | Date of the transaction | 24 July 2018 |
g) | Place of the transaction | London Stock Exchange, AIM |
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Dr John Chiplin |
2 | Reason for the notification | |
a) | Position/status | Chairman and PDMR |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Ordinary Shares of 0.1 pence each |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Purchase of Ordinary Shares |
d) | Price(s) and volume(s) | 2,483 Ordinary Shares 11.7 pence per Ordinary Share |
e) | Aggregated information - Aggregated volume - Price |
2,483 Ordinary Shares 11.7 pence per Ordinary Share |
f) | Date of the transaction | 25 July 2018 |
g) | Place of the transaction | London Stock Exchange, AIM |
- ENDS -
For more information, please contact:
Dr John Chiplin, Chairman Dr Cliff Holloway, CEO | Scancell Holdings plc | +44 (0) 20 3727 1000 |
Freddy Crossley/Emma Earl/Ryan McCarthy
| Panmure Gordon | +44 (0) 20 7886 2500 |
Mo Noonan/Simon Conway | FTI Consulting | +44 (0) 20 3727 1000 |
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat of a wide variety of cancers.
· Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.
For further details, please see our website: www.scancell.co.uk
Follow the stocks
